Davita (DVA) Reaches New 12-Month Low at $45.31

Davita Inc (NYSE:DVA) shares reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $45.31 and last traded at $45.45, with a volume of 7874 shares. The stock had previously closed at $46.92.

Several research analysts have issued reports on DVA shares. Deutsche Bank decreased their price target on shares of Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. SunTrust Banks restated a “hold” rating on shares of Davita in a research report on Wednesday, February 20th. Finally, Robert W. Baird decreased their price target on shares of Davita from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, February 15th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $67.78.

The company has a debt-to-equity ratio of 2.06, a quick ratio of 1.11 and a current ratio of 1.12. The stock has a market capitalization of $7.81 billion, a price-to-earnings ratio of 12.50, a P/E/G ratio of 0.50 and a beta of 1.28.

Davita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.91 earnings per share for the quarter, missing the consensus estimate of $0.95 by ($0.04). Davita had a return on equity of 13.96% and a net margin of 1.15%. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.82 billion. During the same quarter in the previous year, the firm posted $1.05 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, sell-side analysts expect that Davita Inc will post 4.23 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. CSat Investment Advisory L.P. grew its position in Davita by 61.8% during the 4th quarter. CSat Investment Advisory L.P. now owns 581 shares of the company’s stock worth $30,000 after purchasing an additional 222 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in shares of Davita by 467.3% during the 1st quarter. Rehmann Capital Advisory Group now owns 556 shares of the company’s stock valued at $30,000 after buying an additional 458 shares during the period. Quantamental Technologies LLC acquired a new stake in shares of Davita during the 4th quarter valued at $34,000. Fifth Third Bancorp boosted its stake in shares of Davita by 155.7% during the 1st quarter. Fifth Third Bancorp now owns 652 shares of the company’s stock valued at $35,000 after buying an additional 397 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its stake in shares of Davita by 4,995.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,880,451 shares of the company’s stock valued at $37,000 after buying an additional 1,843,544 shares during the period. Hedge funds and other institutional investors own 87.65% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Davita (DVA) Reaches New 12-Month Low at $45.31” was published by Rockland Register and is the sole property of of Rockland Register. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://rocklandregister.com/2019/05/31/davita-dva-reaches-new-12-month-low-at-45-31.html.

About Davita (NYSE:DVA)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Further Reading: What does a bar chart mean for investors?

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.